The spinal muscular atrophy disease gene product (SMN) is crucial for small nuclear ribonuclear protein (snRNP) biogenesis in the cytoplasm and plays a role in pre-mRNA splicing in the nucleus. SMN oligomers interact avidly with the snRNP core proteins SmB, -D1, and -D3. We have delineated the specific sequences in the Sm proteins that mediate their interaction with SMN. We show that unique carboxyl-terminal arginine-and glycine-rich domains comprising the last 29 amino acids of SmD1 and the last 32 amino acids of SmD3 are necessary and sufficient for SMN binding. Interestingly, SMN also interacts with at least two of the U6-associated Sm-like (Lsm) proteins, Lsm4 and Lsm6. Furthermore, the carboxyl-terminal arginine-and glycine-rich domain of Lsm4 directly interacts with SMN. This suggests that SMN also functions in the assembly of the U6 snRNP in the nucleus and in the assembly of other Lsm-containing complexes. These findings demonstrate that arginineand glycine-rich domains are necessary and sufficient for SMN interaction, and they expand further the range of targets of the SMN protein.
Spinal muscular atrophy (SMA) 1 is a neuromuscular disease that results in muscular weakness and atrophy due to degeneration of motor neurons of the spinal cord (1) (2) (3) (4) . Over 98% of SMA patients have mutations or deletions of the Survival Motor Neuron (SMN1) gene, which is present as an inverted repeat on chromosome 5 at 5q13 (5) (6) (7) . Only deletions or mutations in the telomeric copy of SMN (SMN1) lead to SMA (7) (8) (9) (10) (11) (12) (13) (14) . The centromeric copy of the gene (SMN2) produces mostly an alternatively spliced form of SMN deleted of amino acids encoded by exon 7 (SMN⌬Ex7), and SMN2 can only partially compensate for mutations or deletions in SMN1 (7, 15, 16) . Indeed, some patients, instead of complete deletion of SMN1, have shorter deletions of at least exon 7 or single point mutations within the conserved YG domain (17, 18) .
As measured by coimmunoprecipitation from cytoplasmic extracts, SMN exists in a complex with Sm proteins (19) , Gemin2 (formerly SIP1) (19) , Gemin4 (20) , and the DEAD box RNA helicase Gemin3 (21) . The amino terminus of SMN tightly associates with Gemin2, whereas the carboxyl-terminal conserved YG domain is necessary for self-association and interaction with the core snRNP Sm proteins (19, 22) . We have recently demonstrated that oligomerization of SMN through the conserved YG domain is required for efficient interaction with SmB, -D1, and -D3 and suggested that upon oligomerization a high affinity Sm protein binding site is formed (23) .
SnRNPs are formed in the cytoplasm where the core Sm proteins bind to the Sm site on U snRNA, and following hypermethylation of the m 7 G cap to a 2,2,7-trimethyl-gaunosine (m 3 G) cap the snRNP is transported to the nucleus (24 -30) . Using oocyte injections, it was demonstrated that the SMN⅐Gemin2 complex plays a role in spliceosomal snRNP assembly that takes place in the cytoplasm. Injection of Gemin2-specific monoclonal antibodies inhibited, whereas injection of SMN-specific monoclonal antibodies stimulated, snRNP biogenesis (31) . In HeLa cells SMN deleted of the amino-terminal 27 amino acids (SMN⌬N27) functions as a dominant negative mutant sequestering the SMN complex in large cytoplasmic and nuclear bodies (32) . SMN⌬N27 causes accumulation of Sm proteins and U snRNA in the cytoplasm, suggesting that this mutant blocks snRNP assembly prior to cap hypermethylation and nuclear import. In vitro SMN stimulates, whereas SMN⌬N27 and anti-SMN antibodies inhibit, splicing following preincubation in nuclear extracts, demonstrating that SMN may have a role in nuclear regeneration of snRNPs (32) . SnRNP assembly and nuclear splicing are basic cellular functions required for cellular viability. Indeed, mice (33) , Caenorhabditis elegans (34) , and Schizosaccharomyces pombe (35, 36) , all lacking SMN, are not viable, which confirms that SMN plays an essential role. Taken together these data suggest that the SMA phenotype is caused by a motor neuron-specific response to defects in the cytoplasmic assembly and/or nuclear cycling of the splicing machinery.
The biogenesis of U6 snRNP is different from that of the other snRNPs. Unlike other snRNAs, which are transcribed by RNA polymerase II, U6 is transcribed by RNA polymerase III (37) . In addition, U6 does not leave the nucleus (38 -40) , has a ␥-monomethyl triphosphate cap structure (41) , and has a protein core consisting of eight Sm-like (Lsm) proteins (42) (43) (44) . In yeast it has been shown that Lsm4p, Lsm6p, and Lsm7p directly contact the U6 snRNA as measured by ultraviolet light cross-linking experiments (45) . The Lsm⅐U6 RNA complex is relatively salt-labile and dissociates in the presence of competitor RNA, suggesting that the interaction between Lsm and U6 snRNA is more dynamic in nature than that of the Sm core snRNPs, which are extremely stable (44) .
Here we have mapped the regions on the Sm proteins that are responsible for SMN binding. We show that oligomerized SMN interacts with the arginine-and glycine-containing carboxyl-terminal regions of SmB, SmD1, and SmD3. Surpris-ingly, we found that SMN also interacts directly with several of the Lsm proteins. We suggest that the SMN complex has a role in the assembly and/or regeneration of Lsm-containing complexes, including the U6 snRNP.
MATERIALS AND METHODS
Plasmid Construction and Protein Production-All plasmids for expression of Sm and Lsm proteins and deletions or fragments thereof were constructed by polymerase chain reaction amplification of cDNA with specific primers containing restriction sites for subcloning. Expressed sequence tag cDNA clones encoding Lsm2, -3, -4, -5, -6, -7, and -8 (IMAGE clone 1168053, IMAGE clone 278511, ATCC clone 160595, IMAGE clone 2368661 (a kind gift from Bertrand Seraphin), IMAGE clone 925894, and IMAGE clone 2325387, respectively) were obtained and subcloned into pET vectors (Novagen). All constructs used were confirmed by automated DNA cycle sequencing.
All [ 35 S]methionine-labeled proteins were produced in vitro using the TNT T7-coupled reticulocyte system (Promega) in the presence of [ 35 S]methionine (Amersham Pharmacia Biotech) according to the manufacturer's protocol. In Fig. 3 , shown below, all Sm and Sm deletion peptides were expressed from pcDNA3 with an in-frame myc tag (myc-pcDNA3) (46) . All Sm and Sm peptide fragments were produced from pET vectors with (His) 6 -T7 tag (see Fig. 4A, below) . SMN, SMNY272C (tyrosine at position 272 changed to cysteine), SMN⌬YG (deleted of the carboxyl-terminal 26 amino acids), and SMN⌬Ex7 (deleted of amino acids encoded by exon 7) were produced from myc-pcDNA3. These myc tag constructs produce two bands, because translation starts at both the myc tag ATG and the native SMN ATG.
Recombinant GST (Amersham Pharmacia Biotech) and (His)6-T7 (Novagen)-tagged fusion proteins were produced according to the manufacturers' protocols. Following elution from Ni 2ϩ columns all (His) 6 -T7-tagged proteins were extensively dialyzed in 20 mM Tris, pH 7.5, 300 mM NaCl, 2 mM EDTA, 40% glycerol, and 0.5 mM phenylmethylsulfonyl fluoride and stored at Ϫ20°C. For oligomerized GST-SMN/SMN production, two 500-ml cultures, one expressing GST-SMN and one expressing (His) 6 -T7-SMN, were induced and incubated at 17°C with shaking for 16 h. The cultures were centrifuged, and each cell pellet was recovered in 20 ml of resuspension buffer (20 mM Tris, pH 7.5, 400 mM NaCl, 1 mM dithiothreitol, and one tablet per 50 ml of Complete EDTAfree protease inhibitor mixture tablets (Roche Molecular Biochemicals)). Resuspended cells were mixed and lysed by sonication. Triton X-100 was added to 1%, and the lysate was incubated with mild agitation at 4°C for 1 h. The lysate was clarified by centrifugation, and oligomers of SMN were purified on glutathione-Sepharose (Amersham Pharmacia Biotech). Purification of GST-SMN/SMN in this manner produces immobilized oligomerized SMN, which binds to SmB, -D1, and -D3 similarly to the previously reported oligomerized SMN (23) . Prior to use, all recombinant proteins were visualized on Coomassie-stained SDS-polyacrylamide gels to confirm purity and lack of degradation.
In Vitro Binding-All binding reactions were carried out in 1 ml of binding buffer (50 mM Tris, pH 7.5, 200 mM NaCl, 0.2 mM EDTA, 0.05% Nonidet P-40, 2 mM dithiothreitol, and one tablet per 50 ml of Complete EDTA-free protease inhibitor mixture) and incubated 1-2 h at 4°C followed by five washes with 1 ml of binding buffer. All binding assays employed glutathione-Sepharose-immobilized GST fusion proteins (1-2 g). (His) 6 -T7-tagged fusion proteins (0.5-0.7 g) were used for direct binding assays, and for binding of in vitro translated [
35 S]methioninelabeled proteins, 8 l of each translation mixture was used. Bound proteins were separated by SDS-polyacrylamide gel electrophoresis and detected by Western blotting with the T7 tag antibody (Novagen) or autoradiography.
RESULTS

SMN, but Not SMN Mutants Found in SMA Patients, Directly Interacts with SmD1 and SmD3
-Among the eight core Sm proteins, three of them, SmD1, -D3 and -B, have been shown to avidly interact with oligomerized SMN, and only SmB has been shown to interact directly with SMN (23) . To determine if SmD1 and -D3 can also directly interact with SMN, we produced recombinant (His) 6 -T7-tagged SmD1 and -D3. As shown in Fig. 1A , these proteins bound directly to immobilized GST-SMN/SMN but not to GST alone. In the reverse experiment, (His) 6 -T7-tagged SMN bound GST-SmD1 and GSTSmD3 but not GST alone (Fig. 1B) demonstrating that SmD1 and -D3 interact directly with SMN. To determine if, as is the case with SmB, SMN mutations found in some SMA patients are deficient in SmD1 and SmD3 interactions, we tested the ability of in vitro produced, [ 35 S]methionine-labeled, SMN and SMN mutants to interact with GST, GST-SmD1, and GSTSmD3. Fig. 1C shows that SMN but not SMN deleted of amino acids encoded by exon 7 (SMN⌬Ex7), SMN deleted of the YG box (SMN⌬YG), or SMN with tyrosine at position 272 changed to cysteine (SMNY272C) bound GST-SmD1 and GST-SmD3. No binding with GST alone was observed (data not shown). Thus, as is the case with SmB, SMN binds directly to SmD1 and -D3, and SMN mutants reduce these interactions.
Sm Protein Carboxyl-terminal Arginine-and Glycine-rich Domains Are Required for SMN Binding-The Sm protein sequence requirements for SMN interaction have not been elucidated. From visual inspection of the primary sequence of the human Sm proteins we observed that those proteins, which interact most strongly with SMN (SmB, -D1, and -D3), contain extended carboxyl termini. Further examination revealed that the carboxyl termini of these proteins contain clusters of glycine and arginine residues (Fig. 2) . Most strikingly, SmD1 contains nine contiguous glycine-arginine (GR) repeats. SmD3 contains fewer arginine and glycine residues but is markedly arginine-and glycine-rich. SmB contains a very extended carboxyl terminus, which is most noticeably proline-rich but also contains five GRG and three GMR repeats. Because the Sm proteins that interact weakly (or not at all) with SMN do not contain carboxyl-terminal arginine-and glycine-rich domains, we tested whether these domains of SmD1, -D3, and -B were responsible for SMN interaction. We deleted the carboxyl-terminal arginine-and glycine-rich regions and analyzed the ability of these deletions to interact with recombinant GST-SMN/ SMN. These deletions did not eliminate any portion of Sm motifs 1 or 2 common to all Sm proteins (Figs. 2 and 3A) . Deletion of the carboxyl-terminal 99 or 139 amino acids of SmB (SmB⌬c99 and SmB⌬c139, respectively) abolished SMN binding. Deletion of 29 amino acids from the carboxyl terminus of SmD1 (SmD1⌬c29) and 32 amino acids from the carboxyl terminus of SmD3 (SmD3⌬c32) also abolished SMN interaction (Fig. 3B) . Thus, the arginine-and glycine-rich domains of SmB, -D1, and -D3 are necessary for interaction with SMN.
The Carboxyl-terminal Arginine-and Glycine-rich Domains of Sm Proteins Are Sufficient for SMN Binding-To determine whether the arginine-and glycine-rich Sm protein sequences are sufficient for interaction with SMN, carboxyl-terminal fragments were produced separately. In the case of SmB, the carboxyl-terminal 99 (SmBc99) and 139 (SmBc139) amino acids were translated in vitro and SMN binding was assayed. Fig. 4A shows that these peptides did not bind SMN (see "Discussion"). SmD1 carboxyl-terminal 79 (SmD1c79) and 54 (SmD1c54) amino acids and SmD3 carboxyl-terminal 83 (SmD3c83) and 58 (SmD3c58) amino acids were also translated in vitro and tested for binding to immobilized SMN. All of the SmD1 and SmD3 carboxyl-terminal fragments bound SMN with avidities comparable to that of the full-length proteins (Fig. 4B ) and did not bind GST alone (data not shown). In the reverse experiment we fused GST to the carboxyl-terminal 29 and 32 amino acids of SmD1 (GST-SmD1c29) and SmD3 (GST-SmD3c32), respectively. These peptides were produced as recombinant proteins and assayed for interaction with wild type SMN and SMN mutants (SMN⌬Ex7, SMNY272C, and SMN⌬YG). Wild type SMN bound the GST fusion proteins, whereas two of the SMN mutants (SMN⌬Ex7 and SMN⌬YG) showed greatly reduced or undetectable binding (Fig. 4C) . In contrast, under these conditions SMNY272C has only slightly reduced affinity for the carboxyl termini of SmD1 and -D3. GST-SmD1c29 and GSTSmD3c32 interact directly with (His) 6 -T7-tagged SMN (data not shown). Thus, the carboxyl-terminal arginine-and glycinerich domains of SmD1 and -D3 are sufficient for SMN interaction and, like the full-length SmD1 and -D3 proteins, have markedly reduced affinity for SMN deleted of Ex7 or the YG box.
SMN Interacts with the Carboxyl-terminal Arginine-and Glycine-rich Domain of Lsm4 -It has recently been shown that the human U6 snRNP contains Sm-like proteins (Lsm) instead of the Sm proteins found in the U1, U2, U4, and U5 snRNPs (42) (43) (44) . Because the Lsm proteins may function in a similar manner to the core Sm proteins, we were interested to determine if the Lsm proteins can also interact with SMN. To facilitate these experiments we obtained cDNA clones corresponding to the human Lsm2, -3, -4, -5, -6, -7, and -8 proteins. These proteins were then produced by in vitro transcription and translation in the presence of [ 35 S]methionine and tested for binding to SMN. Lsm2, -4, -6, and -7 bound immobilized SMN, with Lsm4 exhibiting higher affinity than the other binders under the assay conditions used (Fig. 5A) . None of these Lsm proteins bound GST alone (data not shown). Interestingly, only one of the Lsm proteins, Lsm4, has an arginineand glycine-rich carboxyl domain (Fig. 2) . To confirm a direct interaction between Lsm4 and SMN and to determine if, like Sm proteins, the carboxyl-terminal arginine-and glycine-rich domain of Lsm4 interacts with SMN, recombinant GST fusions of full-length Lsm4 (GST-Lsm4), Lsm4 deleted of the carboxylterminal 54 amino acids (GST-Lsm4⌬c54), and the carboxylterminal 54 amino acids of Lsm4 (GST-Lsm4c54) were produced separately. As shown in Fig. 5B , GST-Lsm4 and GSTLsm4c54 bound SMN with similar avidities, whereas deletion of the carboxyl-terminal 54 amino acids greatly reduced SMN binding. Thus, the carboxyl-terminal arginine-and glycine-rich domain of Lsm4 is necessary and sufficient for direct interaction with SMN. Because SMN mutants found in SMA patients affect interaction with Sm proteins, we tested their ability to interact with Lsm4. Fig. 5C show that these SMN mutations abolished the binding to Lsm4. DISCUSSION We demonstrate that SMN directly interacts with SmD1 and -D3, and mutants that alter the YG domain of SMN greatly reduce these interactions (Fig. 1) . We have previously shown that peptides encompassing the YG box specifically compete for SmB interaction (19) . Recently, it has been suggested that the tudor domain of SMN is necessary and sufficient for interaction with the Sm proteins. It has also been shown that a point mutation in the tudor domain, which changes a glutamate residue at position 134 to lysine (E134K), reduces Sm interaction (47) . These inconsistent data can be explained if SMN self-association through the YG domain results in the formation of a high affinity Sm binding site, which includes amino acids found in the tudor domain, the YG domain, and possibly other regions of the protein (23) . Regardless of deletion mapping results designed to find the Sm binding site on SMN, it remains clear that SMN mutations found in SMA patients are deficient in Sm protein interaction.
We show that arginine-and glycine-rich domains found at the carboxyl termini of SmB, -D1, and -D3 are necessary for SMN interaction. We further demonstrate that SmD1 and -D3 carboxyl termini with relatively uninterrupted arginine-glycine repeats are also sufficient for SMN interaction. In contrast, SmB has GRG and GMR repeats spread throughout the 151 amino acids from the end of Sm motif 2 to the carboxyl terminus (Fig. 2) . This region, when expressed without the Sm domain, is not sufficient for SMN interaction. This result can be explained if the three-dimensional structure of SmB brings the GRG/GMR repeats into close proximity to form a surface for SMN interaction, and deletion of the Sm domain disrupts this fold. It is possible that this region forms an arginine-and glycine-rich binding surface that is structurally similar to the correspondingly shorter regions of SmD1 and -D3. Crystal structures of heterodimers of SmD3-SmB and SmD1-SmD2 show that the tertiary structure of the Sm domains contains an amino-terminal ␣-helix followed by a bent five-stranded antiparallel ␤-sheet (48) . Unfortunately, the SmB-SmD3 structure did not include amino acids carboxyl-terminal to Sm motif 2, and the carboxyl terminus of SmD1 was not ordered in the crystal structure of SmD1-SmD2. In light of the present work it will be interesting to determine the structure of the carboxylterminal regions of SmB, -D1, and -D3, and it is possible that these regions remain unstructured until bound by SMN.
We show that the carboxyl termini of SmD1 and -D3 are sufficient for interaction with SMN. It is striking that such a small region that, in the case of SmD1, is comprised almost exclusively of arginine-glycine repeats (Fig. 2) is responsible for SMN interaction. This suggests that SMN interacts with any arginine-glycine repeat sequence of sufficient length. However, this is not the case, because heteronuclear RNP A1 and A2, which have regions containing RGG repeats, do not interact with SMN (data not shown).
Electron microscopy (49), Sm-Sm interaction studies (50 -52), x-ray crystallography, and structural modeling suggest that the assembled snRNP Sm core is a seven-membered ring consisting of one copy of each of the Sm proteins, with the snRNA bound in the central hole of the ring (48) . Prior to snRNP assembly, cytoplasmic Sm proteins appear to form SmD1-SmD2 and SmB-SmD3 dimers and SmE-SmF-SmG trimers (50, 53, 54) . The capacity of SMN to interact with at least one component of each of the pre-snRNP Sm complexes (or particularly efficiently with at least the two SmB and SmD complexes) suggests that SMN serves as a scaffold on which the seven-membered snRNP ring forms. SMN readily oligomerizes in vitro (23) and is found in large oligomers in cellular extracts (19, 21) . Oligomeric SMN interaction with non-Sm motif carboxyl-terminal regions of SmB, -D1, and -D3 will likely not interfere with Sm-Sm and Sm-snRNA interactions required for proper snRNP assembly, thus supporting our speculation that SMN can serve as a scaffold for proper snRNP assembly.
Gemin3 and Gemin4, two components of the SMN complex, bind subsets of the Sm proteins. Gemin3 binds SmB, -D2, and -D3, whereas Gemin4, similar to SMN, binds SmB, -D1, -D2, -D3, and -E (20, 21) . The series of SmB, -D1, and -D3 deletion mutants used to map the SMN binding site on these Sm proteins was used in interaction studies with GST-Gemin3 and GST-Gemin4. Although these studies did not exhaustively map the Sm protein sequences required for these interactions, they did demonstrate that the carboxyl-terminal arginine-and glycine-rich sequences of SmB, -D1, and -D3 are dispensable for interaction with Gemin3 and Gemin4 (data not shown). Thus, SMN interacts with the same Sm proteins bound by Gemin3 and Gemin4 but on different regions of the Sm proteins. The SMN complex is, therefore, likely to have a firm multivalent grip on the Sm proteins during snRNP assembly.
We also report here a novel set of interactions between SMN and Lsm proteins (Fig. 5) . The carboxyl terminus of Lsm4 contains an arginine-and glycine-rich domain that, when expressed on its own, is sufficient for direct interaction with SMN (Fig. 5B) . We further show that SMN interacts with Lsm2, -6, and -7. These proteins have no carboxyl-terminal arginine-and glycine-rich domain and, thus, are likely have a different mode of SMN binding. By analogy with the crucial role of the SMN complex in cytoplasmic snRNP assembly and SMN interaction with Sm proteins, the interaction with Lsm proteins suggests that SMN likewise functions in the assembly of U6 snRNP. The fact that SMN interacts with at least two of the Lsm proteins and the similarities in the size and overall shape of Lsm and Sm cores (44, 49) suggest that SMN also serves as a scaffold for Lsm core assembly. This also brings up the possibility that SMN plays a more direct and more extensive role in splicing. Because the Lsm-U6 snRNA interaction is less stable than that of the Sm core with U1, U2, U4, and U5 snRNAs, it has been suggested that the Lsm proteins play a more dynamic role in splicing (44) . Given SMNЈs role in splicing (32) , it is possible that SMN functions in the rearrangement of the Lsm proteins during splicing.
In yeast, Lsm proteins have recently been shown to have a role in mRNA decay. Specifically, there appears to be a complex of Lsm1-7 involved in mRNA degradation in the cytoplasm and a complex of Lsm2-8 involved in splicing in the nucleus (55). Thus, it is possible that SMN also has a role in RNA degradation in the cytoplasm. The role of SMN in Lsm function is currently being investigated.
We originally cloned SMN by interaction with the RGG box of heteronuclear RNP U, and from this work it now emerges to be a general theme that SMN interacts with arginine-and glycine-rich domains. RGG boxes are often found in RNA binding proteins (56, 57) , which is consistent with the role of SMN in assembly of RNPs. Finally, we note that arginines in RGG boxes are often subject to dimethyl arginine modification (58 -61) . It is possible that these arginine-and glycine-rich domains in Sm proteins are similarly modified, and this could serve to modulate their interactions with SMN and to regulate snRNP assembly.
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